BRCA2

BRCA2 and BRCA2 are a human is_associated_with::gene and its is_associated_with::protein product, respectively. The official symbol (BRCA2, italic for the gene, nonitalic for the protein) and the official name (breast cancer 2, early onset) are maintained by the HGNC. is_associated_with::Orthologs, styled Brca2 and Brca2, are common in other is_associated_with::mammal species. BRCA2 is a human is_associated_with::tumor suppressor gene (specifically, a is_associated_with::caretaker gene), found in all humans; its is_associated_with::protein, also called by the is_associated_with::synonym breast cancer type 2 susceptibility protein, is responsible for repairing DNA.

BRCA2 and is_associated_with::BRCA1 are normally expressed in the cells of is_associated_with::breast and other tissue, where they help repair damaged is_associated_with::DNA or destroy cells if DNA cannot be repaired. They are involved in the repair of chromosomal damage with an important role in the error-free repair of DNA double strand breaks. If BRCA1 or BRCA2 itself is damaged by a is_associated_with::BRCA mutation, damaged DNA is not repaired properly, and this increases the risk for is_associated_with::breast cancer. Thus, although the terms "breast cancer susceptibility gene" and "breast cancer susceptibility protein" (used frequently both in and outside the is_associated_with::medical literature) sound as if they describe a proto-oncogene or is_associated_with::oncogene, BRCA1 and BRCA2 are "normal"; it is their mutation that is abnormal.

The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 (13q12.3). The human reference BRCA 2 gene contains 28 exons, and the cDNA has 10,254 base pairs coding for a protein of 3418 amino acids.

The gene was first cloned by scientists at is_associated_with::Myriad Genetics, Endo Recherche, Inc., HSC Research & Development Limited Partnership, and the is_associated_with::University of Pennsylvania.

Methods to diagnose the likelihood of a patient with mutations in is_associated_with::BRCA1 and BRCA2 getting cancer were covered by patents owned or controlled by is_associated_with::Myriad Genetics. Myriad's business model of exclusively offering the diagnostic test led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark is_associated_with::Association for Molecular Pathology v. Myriad Genetics lawsuit.

Function
Although the structures of the is_associated_with::BRCA1 and BRCA2 genes are very different, at least some functions are interrelated. The is_associated_with::proteins made by both is_associated_with::genes are essential for repairing damaged DNA. BRCA2 binds the single strand DNA and directly interacts with the recombinase is_associated_with::RAD51 to stimulate strand invasion a vital step of is_associated_with::homologous recombination. The localization of RAD51 to the DNA double-strand break requires the formation of BRCA1-PALB2-BRCA2 complex. PALB2 (Partner and localizer of BRCA2) can function synergistically with a BRCA2 chimera (termed piccolo, or piBRCA2) to further promote strand invasion. These breaks can be caused by natural and medical radiation or other environmental exposures, but also occur when chromosomes exchange genetic material during a special type of cell division that creates sperm and eggs (is_associated_with::meiosis). Double strand breaks are also generated during repair of DNA cross links. By repairing DNA, these proteins play a role in maintaining the stability of the is_associated_with::human genome and prevent dangerous gene rearrangements that can lead to hematologic and other cancers.

Like BRCA1, BRCA2 probably regulates the activity of other genes and plays a critical role in embryo development.

Clinical significance
Certain variations of the BRCA2 gene increase risks for is_associated_with::breast cancer as part of a is_associated_with::hereditary breast-ovarian cancer syndrome. Researchers have identified hundreds of mutations in the BRCA2 gene, many of which cause an increased risk of cancer. BRCA2 mutations are usually insertions or deletions of a small number of DNA base pairs in the gene. As a result of these mutations, the protein product of the BRCA2 gene is abnormal and does not function properly. Researchers believe that the defective BRCA2 protein is unable to help fix mutations that occur in other genes. As a result, mutations build up and can cause cells to divide in an uncontrolled way and form a tumor.

People who have two mutated copies of the BRCA2 gene have one type of is_associated_with::Fanconi anemia. This condition is caused by extremely reduced levels of the BRCA2 protein in cells, which allows the accumulation of damaged DNA. Patients with Fanconi anemia are prone to several types of is_associated_with::leukemia (a type of blood cell cancer); solid tumors, particularly of the head, neck, skin, and reproductive organs; and is_associated_with::bone marrow suppression (reduced blood cell production that leads to is_associated_with::anemia). Women having inherited a defective BRCA1 or BRCA2 gene have risks for breast and ovarian cancer that are so high and seem so selective that many mutation carriers choose to have prophylactic surgery. There has been much conjecture to explain such apparently striking tissue specificity. Major determinants of where BRCA1 and BRCA2 associated hereditary cancers occur are related to tissue specificity of the cancer pathogen, the agent that causes chronic inflammation or the carcinogen. The target tissue may have receptors for the pathogen, become selectively exposed to carcinogens and an infectious process. An innate genomic deficit impairs normal responses and exacerbates the susceptibility to disease in organ targets. This theory also fits data for several tumor suppressors beyond BRCA1 or BRCA2. A major advantage of this model is that it suggests there are some options in addition to prophylactic surgery.

In addition to breast cancer in men and women, mutations in BRCA2 also lead to an increased risk of ovarian, is_associated_with::Fallopian tube, prostate, and is_associated_with::pancreatic cancers, as well as is_associated_with::malignant melanoma. In some studies, mutations in the central part of the gene have been associated with a higher risk of is_associated_with::ovarian cancer and a lower risk of is_associated_with::prostate cancer than mutations in other parts of the gene. Several other types of cancer have also been seen in certain families with BRCA2 mutations.

In general, strongly inherited gene mutations (including mutations in BRCA2) account for only 5-10% of breast cancer cases; the specific risk of getting breast or other cancer for anyone carrying a BRCA2 mutation depends on many factors.

Germ line BRCA2 mutations and founder effect
All germ line BRCA2 mutations identified to date have been inherited, suggesting the possibility of a large “founder” effect in which a certain mutation is common to a well-defined population group and can theoretically be traced back to a common ancestor. Given the complexity of mutation screening for BRCA2, these common mutations may simplify the methods required for mutation screening in certain populations. Analysis of mutations that occur with high frequency also permits the study of their clinical expression. A striking example of a founder mutation is found in Iceland, where a single BRCA2 (999del5) mutation accounts for virtually all breast/ovarian cancer families. This frame-shift mutation leads to a highly truncated protein product. In a large study examining hundreds of cancer and control individuals, this 999del5 mutation was found in 0.6% of the general population. Of note, while 72% of patients who were found to be carriers had a moderate or strong family history of breast cancer, 28% had little or no family history of the disease. This strongly suggests the presence of modifying genes that affect the phenotypic expression of this mutation, or possibly the interaction of the BRCA2 mutation with environmental factors. Additional examples of founder mutations in BRCA2 are given in the table below.

Interactions
BRCA2 has been shown to interact with


 * BRE,
 * is_associated_with::BARD1,
 * is_associated_with::BCCIP,
 * is_associated_with::BRCA1,
 * is_associated_with::BRCC3,
 * is_associated_with::BUB1B,
 * CREBBP,
 * is_associated_with::C11orf30,
 * is_associated_with::FANCD2,
 * is_associated_with::FANCG,
 * FLNA,
 * is_associated_with::HMG20B,
 * is_associated_with::P53,
 * is_associated_with::PALB2,
 * is_associated_with::PCAF,
 * is_associated_with::PLK1,
 * is_associated_with::RAD51,
 * RPA1,
 * is_associated_with::SHFM1 and
 * SMAD3.

Domain architecture
BRCA2 contains a number of 39 is_associated_with::amino acid repeats that are critical for binding to is_associated_with::RAD51 (a key protein in DNA recombinational repair) and resistance to methyl methanesulphonate treatment.

The BRCA2 helical domain adopts a is_associated_with::helical structure, consisting of a four-helix cluster core (alpha 1, alpha 8, alpha 9, alpha 10) and two successive beta-hairpins (beta 1 to beta 4). An approximately 50-amino acid segment that contains four short helices (alpha 2 to alpha 4), meanders around the surface of the core structure. In BRCA2, the alpha 9 and alpha 10 helices pack with the BRCA2 OB1 domain through van der Waals contacts involving is_associated_with::hydrophobic and aromatic residues, and also through side-chain and backbone is_associated_with::hydrogen bonds. This domain binds the 70-amino acid is_associated_with::DSS1 (deleted in split-hand/split foot syndrome) protein, which was originally identified as one of three is_associated_with::genes that map to a 1.5-Mb locus deleted in an inherited developmental malformation syndrome.

The BRCA OB1 domain assumes an OB fold, which consists of a highly curved five-stranded is_associated_with::beta-sheet that closes on itself to form a is_associated_with::beta-barrel. OB1 has a shallow groove formed by one face of the curved sheet and is demarcated by two loops, one between beta 1 and beta 2 and another between beta 4 and beta 5, which allows for weak single strand DNA binding. The domain also binds the 70-amino acid is_associated_with::DSS1 (deleted in split-hand/split foot syndrome) protein.

The BRCA OB3 domain assumes an OB fold, which consists of a highly curved five-stranded is_associated_with::beta-sheet that closes on itself to form a is_associated_with::beta-barrel. OB3 has a pronounced groove formed by one face of the curved sheet and is demarcated by two loops, one between beta 1 and beta 2 and another between beta 4 and beta 5, which allows for strong is_associated_with::ssDNA binding.

The Tower domain adopts a is_associated_with::secondary structure consisting of a pair of long, antiparallel alpha-helices (the stem) that support a three-helix bundle (3HB) at their end. The 3HB contains a is_associated_with::helix-turn-helix motif and is similar to the DNA binding domains of the is_associated_with::bacterial site-specific is_associated_with::recombinases, and of is_associated_with::eukaryotic Myb and is_associated_with::homeodomain is_associated_with::transcription factors. The Tower domain has an important role in the tumour suppressor function of BRCA2, and is essential for appropriate binding of BRCA2 to DNA.

Patents, enforcement, litigation, and controversy
A patent application for the isolated is_associated_with::BRCA1 gene and cancer-cancer promoting mutations, as well as methods to diagnose the likelihood of getting breast cancer, was filed by the University of Utah, National Institute of Environmental Health Sciences (NIEHS) and is_associated_with::Myriad Genetics in 1994; over the next year, Myriad, in collaboration with other investigators, isolated and sequenced the BRCA2 gene and identified relevant mutations, and the first BRCA2 patent was filed in the U.S. by Myriad and the other institutions in 1995. Myriad is the exclusive licensee of these patents and has enforced them in the US against clinical diagnostic labs. This business model led from Myriad being a startup in 1994 to being a publicly traded company with 1200 employees and about $500M in annual revenue in 2012; it also led to controversy over high prices and the inability to get second opinions from other diagnostic labs, which in turn led to the landmark is_associated_with::Association for Molecular Pathology v. Myriad Genetics lawsuit. The patents begin to expire in 2014.

According to an article published in the journal, Genetic Medicine, in 2010, "The patent story outside the United States is more complicated.... For example, patents have been obtained but the patents are being ignored by provincial health systems in Canada. In Australia and the UK, Myriad’s licensee permitted use by health systems, but announced a change of plans in August 2008. ... Only a single mutation has been patented in Myriad’s lone European-wide patent, although some patents remain under review of an opposition proceeding. In effect, the United States is the only jurisdiction where Myriad’s strong patent position has conferred sole-provide status." Peter Meldrum, CEO of Myriad Genetics, has acknowledged that Myriad has "other competitive advantages that may make such [patent] enforcement unnecessary" in Europe.

Legal decisions surrounding the BRCA1 and BRCA2 patents will affect the field of genetic testing in general. In June 2013, in Association for Molecular Pathology v. Myriad Genetics (No. 12-398), the US Supreme Court unanimously ruled that, "A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated," invalidating Myriad's patents on the BRCA1 and BRCA2 genes. However, the Court also held that manipulation of a gene to create something not found in nature could still be eligible for patent protection. The is_associated_with::Federal Court of Australia came to the opposite conclusion, upholding the validity of an Australian Myriad Genetics patent over the BRCA1 gene in February 2013, but this decision is being appealed and the appeal will include consideration of the US Supreme Court ruling.